Search Results - "Pryor, D.I"

Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma by Pryor, D.I, Burmeister, E, Burmeister, B.H, Poulsen, M.G, Porceddu, S.V

“…Summary To describe the distinct patterns of severe anterior stomatitis seen with concurrent cetuximab and radiotherapy (RT) compared to chemoRT or altered…”
Get full text

Cost-Effectiveness of Stereotactic Body Radiotherapy vs. Thermal Ablation for Primary Renal Cell Carcinoma: Analysis of the FASTRACK II Trial by Vargas, C., Carrello, J., Siva, S., Davey, R., Bressel, M., Pryor, D.I., De Abreu Lourenco, R.

“…FASTRACK II (NCT02613819) was a prospective single-arm trial that demonstrated the safety and efficacy of stereotactic ablative body radiotherapy (SABR) in…”
Get full text

Stereotactic Ablative Radiotherapy For Hepatocellular Carcinoma: A Systematic Review And Meta-Analysis Of Local Control, Survival, And Toxicity Outcomes by Shanker, M.D., Soon, W.S., Lee, Y.Y., Liu, H., Pryor, D.I.

Get full text

Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases by Chow, R., Biswas, T., Liu, H., Pryor, D.I., Chu, W., Swaminath, A., Chung, H.T., Schellenberg, D., Grindrod, N., Lee, Y.Y., Gaede, S., Sachdeva, R., Lock, M.I.

“…Primary and secondary liver cancer incidence is growing and has a poor prognosis. The standard use of radiation has been hampered by studies with a wide range…”
Get full text

TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II) by Siva, S., Bressel, M., Sidhom, M., Sridharan, S., Vanneste, B., Davey, R., Ruben, J., Foroudi, F., Higgs, B.G., Lin, C., Raman, A., Hardcastle, N., Shaw, M., Mancuso, P., Lawrentschuk, N., Wood, S., Brook, N., Kron, T., Martin, J.M., Pryor, D.I.

“…Stereotactic body radiotherapy (SBRT) is an emerging non-invasive alternative for primary renal cell cancer (RCC) in patients unsuitable for surgery. The…”
Get full text

Multi-Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer by Sutera, P., Deek, M.P., Jing, Y., Pryor, D.I., Huynh, M.A., Koontz, B.F., Mercier, C., Ost, P., Kiess, A.P., Conde-Moreno, A.J., Stish, B.J., Bosetti, D.G., Siva, S., Berlin, A., Kroeze, S., Corcoran, N., Trock, B., Gillessen, S., Tran, P.T., Sweeney, C.

“…Several prospective trials in oligometastatic castration sensitive prostate cancer (omCSPC) have shown metastasis-directed therapy (MDT) can delay time to…”
Get full text

Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomized Phase II Trial by Siva, S., Bressel, M., Kron, T., Mai, T., Le, H.V., Montgomery, R., Hardcastle, N., Rezo, A., Gill, S., Higgs, B.G., Pryor, D.I., De Abreu Lourenco, R., Awad, R., Chesson, B., Eade, T.N., Skala, M., Sasso, G., Wong, W., Vinod, S., Ball, D.

Get full text

Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus by Effeney, R., Shaw, T., Burmeister, B.H., Burmeister, E., Harvey, J., Mai, G.T., Thomas, J., Barbour, A.P., Smithers, B.M., Pryor, D.I.

“…To analyse outcomes and patterns of failure following dose-escalated definitive chemoradiotherapy (CRT) for oesophageal squamous cell carcinoma using…”
Get full text

O25. Results of a prospective PET-guided management of the neck study in node positive head and neck squamous cell carcinoma (HNSCC) following curative radiotherapy with or without concurrent chemotherapy by Porceddu, S.V., Pryor, D.I., Doughton, J., Burmeister, E., Burmeister, B.H., Poulsen, M.G.

Get full text